AMG 706 in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome
ClinicalTrials.gov Identifier: NCT00427349

A Randomized Double -Blind Phase III Study of RAD 001 10 mg/d Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumor (NET)
Conditions: Carcinoma; Islet Cell Tumor
ClinicalTrials.gov Identifier: NCT00510068

A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
Conditions: Carcinoma; Islet Cell
ClinicalTrials.gov Identifier: NCT00428597

Avastin (Bevacizumab) and RAD 001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Conditions: Neuroendocrine Carcinoma
ClinicalTrials.gov Identifier: NCT00607113

BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors
Conditions:Gastrointestinal Carcinoid Tumor; Lung Cancer; Neuroendocrine Carcinoma;
Unspecified Adult Solid Tumor, Protocol Specific
ClinicalTrials.gov Identifier: NCT00346385

Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor;
ClinicalTrials.gov Identifier: NCT00602082

Clinical and Translational Study of MK-0646 in Patients with Metastatic Neuroendocrine Tumors (NET)
Conditions: Neuroendocrine Tumors; Metastatic Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00610129

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Lung Cancer;
Neoplastic Syndrome; Neuroendocrine Carcinoma of the Skin
ClinicalTrials.gov Identifier: NCT00227617

Efficacy and Safety of Everolimus (RAD001) in Female or Male Patients 18 Years or Older With Advanced Neuroendocrine Tumors
Condition: Advanced Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00510068

Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00326469

Lithium for Low-Grade Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor
ClinicalTrials.gov Identifier: NCT00501540

Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Lung Cancer;
Multiple Endocrine Neoplasia 1 and 2 (men1, men2); Neoplastic Syndrome
ClinicalTrials.gov Identifier: NCT00454363

Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable
Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00398320

Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
Conditions: Neuroendocrine Tumor; Islet Cell Tumor
ClinicalTrials.gov Identifier: NCT00434109

RAD 001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00576680

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Conditions: Brain and Central Nervous System Tumors; Gastrointestinal Carcinoid Tumor;
Islet Cell Tumor; Pheochromocytoma; Sarcoma;
ClinicalTrials.gov Identifier: NCT00049023

Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00442533

Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Condition: Metastatic Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00590343

Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features
Condition: Carcinoid; Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00314925

Study of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine Tumours
Conditions: Endocrine Tumors;
ClinicalTrials.gov Identifier: NCT00353496

The Safety and Efficacy of CPTK 787/ZK222584 in Patients With Metastatic Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
ClinicalTrials.gov Identifier: NCT00627198